THERAPEUTIC VALUE OF PROBENECID (BENEMID®) IN GOUT

Publisher Website
Google Scholar
Abstract
Probenecid (benemid®) was first introduced into clinical medicine by Boger1 as an adjunct to penicillin and paraaminosalicylic acid therapy. Probenecid has been found to be a powerful agent that reversibly inhibits renal tubular transfer, suppressing tubular secretion of penicillin, paraaminosalicylic acid, paraaminohippuric acid, and phenolsulfonphthalein.2 In this respect it is similar to carinamide; but while the latter is required in doses of 18 to 24 gm. per day for its tubular effect, probenecid accomplishes the same results in doses of 2 gm. daily. That probenecid, like carinamide, is also capable of blocking tubular reabsorption of glomerular constituents was demonstrated by Schneider and Corcoran,3 who were able to increase the excretion of phosphate by administration of the drug. Gutman, acting on the report by Wolfson and associates4 that carinamide was a uricosuric agent, demonstrated that probenecid had a similar effect, presumably by blocking the partial reabsorption of